

A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes

Rodrigo Garcia-Salinas, Sebastian Magri, Alvaro Ruta, Santiago Ruta

Rheumatology Unit, Hospital Italiano de La Plata, Universidad Nacional de La Plata, Argentina

Correspondence: Rodrigo Garcia Salinas, Rheumatology Unit, Hospital Italiano de La Plata, 51 street, 1725, La Plata, Buenos Aires Province, Argentina.

Tel.: + 54 221 512 9500

E-mail: gsalinasrodrigo@gmail.com

Key words: adalimumab, biosimilars, rheumatoid arthritis, psoriatic arthritis, ultrasonography.

Summary

Objective. Limited data in Latin America exists regarding the efficacy of switches from original biologicals to biosimilars in real-life scenarios. Currently, no studies assess this switch using imaging. The objective of this study was to evaluate clinical, functional, ultrasonographic, and radiological responses in a group of patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) switched from original adalimumab (oADA) to biosimilar (bADA) (GP2017).

Methods. A prospective cohort study included diagnosed RA and PsA patients undergoing oADA treatment. At the baseline visit, blood analysis, X-rays, ultrasound, and an interview for sociodemographic and clinical data were conducted. Evaluators were unaware of each other's data. Patients switched to bADA during follow-up and were assessed in the same program within 3 to 12 months post-switch (only including patients with all evaluations).

Results. Out of 270 RA cohort patients, 35 met the criteria for complete pre- and post-control post-switch to bADA (GP2017), along with 15 PsA patients. The mean time between the switch and the second evaluation was 4.1 months (interquartile range 7). No statistical differences were observed in disease activity or functional capacity. Regarding imaging, no difference was found in X-ray erosion number; however, ultrasonography revealed decreased power Doppler (PD) activity, but not grayscale changes. No differences in acute phase reactants, joint count, or patient visual analog scale were observed between controls.

Conclusions. In this analysis of the switch between oADA and bADA, no differences were found in disease activity, functional capacity, or radiographic progression. Ultrasonography indicated improvement of PD findings.

Introduction

Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are chronic autoimmune conditions characterized by joint inflammation and damage, contributing significantly to patient morbidity (1, 2). The arrival of biological therapies, particularly adalimumab

(ADA), has changed the management of these conditions, demonstrating improved clinical outcomes and enhanced quality of life (3).

The implementation of biosimilars in rheumatic diseases has gained a place, emphasizing their comparable efficacy and safety to reference products. Not only do biosimilars offer potential economic benefits, but they also enhance accessibility to effective treatments for a broader patient population (4).

The introduction of a biosimilar of tumor necrosis factor (TNF) blockers, especially ADA, raises the need to perform evaluations of the efficacy and safety associated with the switch from the original ADA (oADA) to the biosimilar counterpart (bADA) in real-life scenarios, beyond the clinical trials that support the evidence (5). One of the primary challenges is the potential development of anti-drug antibodies, which could impact the efficacy and safety of these therapies. Additionally, the nocebo effect, where negative expectations from patients or clinicians regarding the biosimilar may influence treatment outcomes, poses a significant hurdle in clinical practice. The use of bADA in Latin America is widespread, but published data is scarce (4, 5).

The increasing role of imaging, notably ultrasonography (US), in assessing disease activity and treatment response has become integral to rheumatological practice. However, the impact of transitioning from oADA to bADA on imaging parameters remains an underexplored area in the existing body of literature (6).

The primary objective of this research is to comprehensively evaluate the clinical, functional, ultrasonographic, and radiological responses in RA and PsA patients under the first biological treatment, undergoing a switch from oADA to bADA.

Materials and Methods

This prospective longitudinal study included consecutive patients older than 18 years with a diagnosis of RA and PsA, treated with oADA as a first line of biological treatment (failure of conventional synthetic disease-modifying anti-rheumatic drugs) who were evaluated by the Reuma-Check program and switched to bADA (GP2017) within one year. The baseline evaluation was performed between August 2022 and December 2023. In brief, the Rheuma-Check Program is a circuit designed for the early diagno-

sis of rheumatic conditions and the systematic follow-up of patients. The different physicians involved included laboratory, imaging, and clinical specialists. This setup is integral to the Reuma-Check program, which operates through a station-based evaluation process. Each evaluator conducts his assessment independently, without access to the results obtained by others. This design aims to prevent any potential bias and ensure that the findings from one domain do not influence the evaluations in another. After switching to bADA, a second evaluation under the same standardized protocol was conducted within one year of the baseline assessment (7, 8).

Baseline assessment

Demographic features were assessed. Clinical data, including disease duration and comorbidities, were collected. The musculoskeletal assessment was performed according to standard clinical procedures and included: tender joint count (TJC 28), swollen joint count (SJC 28), visual analog scale for patient's (VAS patient global) and physician's (VAS physician global) global perception of disease activity. The function was evaluated by the Argentinean version of the Health Assessment Questionnaire-Disability Index (9).

Erythro sedimentation rate (ESR) and C-reactive protein (CRP) were determined in all patients on the same day as the clinical and image evaluation.

All US examinations were performed by the same rheumatologist with extensive experience in this imaging technique, on the same day as the clinical assessment. Patients were asked not to talk with the operator during the US examination. A MyLab 25 Gold (Esaote) machine with a multifrequency linear transducer (6-18 MHz) was used. The following joints were bilaterally investigated: wrist, 2nd to 5th metacarpophalangeals and 2nd to 5th proximal interphalangeals, giving a total of 22 assessed joints per patient. The standardized scanning method recommended by the European Alliance of Associations for Rheumatology was used, and joint cavity widening (10), due to the presence of synovial fluid and/or synovial hypertrophy (grayscale synovitis) according to the OMERACT ("Outcomes Measures in Rheumatology") preliminary definitions (11), was evaluated at each joint. All joints were evaluated with the power Doppler (PD) technique to assess the presence of increased, abnormal synovial vascularization. Intraarticular PD signal was scored on a semiquantitative scale from 0 to 3 (grade 0 = no intraarticular PD signal; grade 1 = presence of a single PD signal; grade 2 = more than two confluent foci of PD signal but occupying less than 50% of intra-articular area; grade 3 = PD signal in more than 50% of the intraarticular area). To maximize PD sensitivity and trying to avoid artifacts, the settings of PD were adjusted as follows: low pulse frequency repetition (between 500 and 1000 Hz), dynamic range 20-40 dB, low wall filters (2, 3), and PD gain below the level at which color noise appeared in the underlying bone (12-14). For the purposes of this study, patients were considered to have positive US if they had at least one joint with a positive PD signal grade 2-3 and to be improved when the PD signal dropped to grade 0 or 1. Findings were defined as absence or presence (yes/no). X-rays of both hands and feet were performed on the same day. The presence or absence (yes/no) of bone erosions was determined by an experienced medical rheumatologist at any joint included on the Sharp/van der Heijde score.

Follow-up

Clinical, laboratory, and imaging data at baseline were uploaded to an electronic clinical system report. After one year, an evaluation

identical to the baseline was carried out in the same circuit with the same evaluations, in those patients who had been switched from oADA to bADA (GP2017) for less than one year. All procedures and steps of the Reuma-Check program are detailed in the cited publications (7, 8).

Statistical analysis

Descriptive statistic was used to summarize patients' characteristics. Continuous variables were expressed as medians and interquartile range (IQR) or as means and standard deviation, and categorical variables were expressed as percentages with their corresponding 95% confidence intervals. The comparison between disease activity assessments, Health Assessment Questionnaire (HAQ) results, laboratory parameters, and images was performed using parametric and non-parametric tests for continuous variables and the chi-squared test for categorical variables.

Results

Of the 270 patients in our RA cohort, 35 met the criteria: first biological treatment, switch from oADA to bADA (GP2017) with complete pre- and post-monitoring in the Reuma-Check circuit. Of the PsA cohort (70 patients), 15 patients met this premise. Table 1 shows the baseline characteristics before the switch.

The mean number of months of treatment with the oADA was 4 (IQR 6), and the mean time between the switch and the second evaluation was 4.1 months (IQR 7).

No statistical differences were observed in terms of median disease activity pre- and post-switch: Disease Activity Score-28 3.7 (IQR: 2) vs. 3.5 (IQR: 1.8), $p=0.6$, or functional capacity (HAQ) 0.8 (IQR: 0.1) vs. 1.1 (IQR: 0.11), $p=0.7$. Figure 1 shows the values of the Simplified Disease Activity Index and the Clinical Disease Activity Index.

Regarding the image evaluation, no difference was found in the proportion of erosions in X-rays (47% vs. 48%, $p=0.7$); the comparison of US examinations showed a decreased activity by PD (27% vs. 12%, $p=0.03$), but not by grayscale evaluation, after the switch (Figure 1).

There was no difference between visits in acute phase reactants (ESR mm/hr: 30 vs. 27.5, $p=0.2$, CRP mg/L: 3 vs. 4, $p=0.09$), tender and swollen joint count (TJC: 4 vs. 5, $p=0.4$, SJC: 2.9 vs 3.1, $p=0.6$), and VAS of the patient's activity (51 vs. 47 mm, $p=0.08$).

Discussion

This study evaluates the impact of switching from oADA to its biosimilar in patients with RA and PsA and analyzes clinical, functional, ultrasonographic, and radiological responses in patients undergoing this transition.

In the development of biosimilars, physical-chemical characterization and preclinical studies are more important than clinical trials, which are limited to transition or switch studies, or interchangeability studies in the most sensitive indications for the drug (15, 16). However, once approval is achieved by regulatory agencies, the development of real-world evidence (RWE) is essential for the development of evidence in the switch (17).

In rheumatology, ADA stands out as the TNF blocker with the most extensive range of indications, encompassing conditions such as RA and PsA. Notably, ADA serves as the benchmark drug in the advancement of more sophisticated therapies for these diseases

(18). At present, it is the treatment with the highest number of biosimilars developed in rheumatology, all of which adhere to the rigorous quality standards mandated by major regulatory agencies (19). Among these biosimilars, GP2017, developed by Sandoz (Basel, Switzerland), has a comprehensive development program that includes the ADMYRA study for RA (20) and ADACCES for psoriasis (21). Importantly, the latter incorporates multiple switch arms, providing compelling evidence of GP2017 interchangeability with the oADA.

The Nord-Switch study of infliximab was the pioneer in rheumatology for the switching from an original biologic to a biosimilar based on clinical evidence with pharmacoeconomic bases (22). The body of evidence regarding the transition from original drugs to biosimilars within rheumatology has been steadily expanding, owing to investigations conducted by independent research centers, real-life/pharmacovigilance registries, and data derived from healthcare payers. These studies unequivocally indicate switching does not escalate the frequency of adverse events or events associated with immunogenicity. Moreover, compelling information emerges from this body of evidence since the adoption of biosimilars yields substantial economic benefits for the health-

care system. These advantages manifest in the form of resource savings and increased accessibility to advanced therapies in rheumatology (17, 23-25). Among others, the validation of GP2017 in real-life studies, supported by the research of Nabi *et al.* from the DANBIO registry, underscores the robustness of the findings and adds confidence to the observed positive outcomes (26).

Table 1. Baseline characteristics of the rheumatoid arthritis and psoriatic arthritis cohort.

	n: 50
Baseline characteristics	
Female sex, %	60
Age (years), mean (SD)	54 (14)
Disease duration (months), median (IQR)	24 (50)
School years, mean (SD)	12.5 (3)
Weight (kg), mean (SD)	78 (17)
TBQ, %	34
Early disease (≤ 2 years), %	50
RF+, %	74
ACPA +, % (RA: 35)	53
Double seropositive, % (RA: 35)	48
X-ray hands erosions +, %	47
Synovitis US (grayscale), %	37
Ultrasonographic synovitis (power-doppler), %	28
TJC (28), mean (SD)	2.9 (2.1)
SJC (28), mean (SD)	4 (3.5)
CRP + (>5 mg/L), %	35
CRP titer (mg/L), median (IQR)	3 (9)
ESR (mm 1 h), mean (SD)	30 (24)
VAS patient (mm), mean (SD)	51 (21)
VAS physician (mm), mean (SD)	37 (19)
DAS28, mean (SD)	3.8 (1.2)
SDAI, mean (SD)	16 (11)
CDAI, mean (SD)	14.8 (8)
HAQ, mean (SD)	0.75 (0.48)
Comorbidities	
Comorbidities (any), %	55
Anemia ($Hb \leq 12$), %	18
Cardiovascular disease, %	39
Diabetes, %	17
Interstitial lung disease, %	9
Cancer, %	8
MACE, %	5
Dyslipidemia, %	16
Associated treatment	
Methotrexate, %	83
Oral corticosteroids (any dose), %	43
Oral corticosteroids (>10 mg), %	16

SD, standard deviation; TBQ, tobacco smoking; RF+, rheumatoid factor positive; ACPA, anti-citrullinated peptide antibody; RA, rheumatoid arthritis; US, ultrasound; TJC, Tender joint count; SJC, swollen joint Count; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; VAS, visual analog scale; DAS28, Disease Activity Score-28; SDAI, Simplified Disease Activity Index; CDAI, Clinical Disease Activity Index; HAQ, Health Assessment Questionnaire; Hb, hemoglobin; MACE, major adverse cardiac events. ACPA and RF were assessed only in patients with rheumatoid arthritis.




Figure 1. Clinical, functional, and imaging assessments before and after the switch from original adalimumab (oADA) to its biosimilar (GP2017). **A)** Comparison of disease activity [Disease Activity Score-28 (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI)] and functional status (HAQ) between baseline (1st control) and follow-up (2nd control) evaluations; **B)** imaging outcomes, including proportion of patients with radiographic erosions, grayscale ultrasonographic synovitis (US-GS), and power Doppler activity (US-PD). A significant decrease in PD activity was observed after the switch ($p=0.03$). No significant changes were found in the other parameters.

The aforementioned evidence originates predominantly from the European continent. Despite the presence of regulations about the utilization of biosimilars by health authorities or regulatory agencies in Latin America, the lack of RWE in the region accentuates the significance of our research findings. Our study not only addresses this gap but also contributes insights into the decision-making processes of specialist physicians and the broader health-care system, together with the guidelines developed in our region by the Pan-American League of Associations for Rheumatology (27, 28).

In addition to the efficacy results, our research introduces a distinctive element by providing evidence regarding the impact of the switch on imaging, a facet not explored in RWE studies of biosimilars. We have demonstrated that there is no discernible impact from a radiographic perspective in a qualitative manner, albeit acknowledging that the evaluation time (less than one year) may be insufficient to establish conclusions. US evaluation, a secure and accessible method, indicates improved PD findings, potentially indicating that patients maintained a positive response to ADA regardless of the switch to its biosimilar.

Importantly, the utilization of objective assessments, such as imaging, serves to mitigate the placebo effect that may arise from biosimilar switching. This approach enhances the credibility of our findings and underscores the objective nature of the observed improvements. Another positive aspect of the study lies in the method of obtaining patient information, conducted within the Reuma-Check circuit, a protocolized evaluation program validated in various publications, enabling the collection of comprehensive and standardized data (29).

Finally, we must recognize several weaknesses in our study. Firstly, the study is hampered by a relatively small sample size, as it exclusively encompasses patients initiating their treatment with biological therapies in a single center. This approach introduces selection and indication biases that warrant consideration. Moreover, the small sample size limits the power of the study to detect subtle differences associated with biosimilar switching. This constraint significantly impacts the generalizability of our findings to broader patient populations and reinforces the necessity of larger multicenter studies to validate our results and draw more definitive conclusions. Furthermore, the absence of a control group that continued treatment with the oADA limits our ability to distinguish whether the observed outcomes were specifically related to the biosimilar switch or attributable to other factors. Additionally, the study is constrained by a limited evaluation period (one year) and, as of the time of this publication, lacks an ongoing follow-up.

Conclusions

In conclusion, the study suggests that transitioning from oADA to bADA (GP2017) as the first-line biological treatment for RA and PsA patients does not appear to lead to significant changes in disease activity or functional capacity. Radiographic assessments exhibited no changes in X-ray erosions before and after the transition. However, US evaluations indicated a decreased PD activity following the switch. Acute phase reactants, joint count, and patient-reported activity did not change. While these findings are encouraging, they should be interpreted in the context of the study's limitations, including the small sample size and the absence of a control group continuing with oADA.

References

1. Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis. *JAMA* 2018; 320: 1360-72.
2. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. *N Engl J Med* 2017; 376: 957-70.
3. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. *Ann Rheum Dis* 2014; 73: 492-509.
4. Aladul MI, Fitzpatrick RW, Chapman SR. The effect of new biosimilars in rheumatology and gastroenterology specialties on UK healthcare budgets: results of a budget impact analysis. *Res Social Adm Pharm* 2019; 15: 310-7.
5. Heo YA. GP2017: an adalimumab biosimilar. *BioDrugs* 2018; 32: 635-8.
6. Carstensen SMD, Terslev L, Jensen MP, Østergaard M. Future use of musculoskeletal ultrasonography and magnetic resonance imaging in rheumatoid arthritis. *Curr Opin Rheumatol* 2020; 32: 264-72.
7. Ruta S, Prado ES, Chichande JT, Ruta A, Salvatori F, Magri S, et al. EULAR definition of "arthralgia suspicious for progression to rheumatoid arthritis" in a large cohort of patients included in a program for rapid diagnosis: role of auto-antibodies and ultrasound. *Clin Rheumatol* 2020; 39: 1493-9.
8. Garcia-Salinas R, Magri S, Mareco J, Jaldin R, Perez R, Ruta S, et al. Arthralgia with risk of progression to psoriatic arthritis: role of clinical assessments and ultrasound as prognostic factors. *Rheumatology* 2024; keae562.
9. Citera G, Arriola MS, Maldonado-Cocco JA, Rosemffet MG, Sanchez MM, Goni MA et al (2004) Validation and crosscultural adaptation of an Argentine Spanish version of the Health Assessment Questionnaire disability index. *J Clin Rheumatol* 10(3):110-115
10. Backhaus M, Burmester GR, Gerber T, Grassi W, Machold KP, Swen WA, et al. Guidelines for musculoskeletal ultrasound in rheumatology. *Ann Rheum Dis* 2001; 60: 641-9.
11. Wakefield RJ, Balint P V, Szkudlarek M, Filippucci E, Backhaus M, D'Agostino MA, et al. Musculoskeletal ultrasound including definitions for ultrasonographic pathology. *J Rheumatol* 2005; 32: 2485-7.
12. Gutierrez M, Filippucci E, Salaffi F, Di Geso L, Grassi W. Differential diagnosis between rheumatoid arthritis and psoriatic arthritis: the value of ultrasound findings at metacarpophalangeal joints level. *Ann Rheum Dis* 2011; 70: 1111-4.
13. Naredo E, Bonilla G, Gamero F, Uson J, Carmona L, Laffon A. Assessment of inflammatory activity in rheumatoid arthritis: a comparative study of clinical evaluation with grey scale and power Doppler ultrasonography. *Ann Rheum Dis* 2005; 64: 375-81.
14. Naredo E, Gamero F, Bonilla G, Uson J, Carmona L, Laffon A. Ultrasonographic assessment of inflammatory activity in rheumatoid arthritis: comparison of extended versus reduced joint evaluation. *Clin Exp Rheumatol* 2005; 23: 881-4.
15. Kozlowski S, Woodcock J, Midthun K, Behrman Sherman R. Developing the nation's biosimilars program. *N Engl J Med* 2011; 365: 385-8.
16. Schiestl M, Stangler T, Torella C, Čepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. *Nat Biotechnol* 2011; 29: 310-2.
17. Glinborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A,

- Espesen J, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. *Ann Rheum Dis* 2019; 78: 192-200.
18. Norman P. Humira®: recent developments. *Pharm Pat Anal* 2017; 6: 89-90.
 19. Zhao S, Chadwick L, Mysler E, Moots RJ. Review of biosimilar trials and data on adalimumab in rheumatoid arthritis. *Curr Rheumatol Rep* 2018; 20: 57.
 20. Wiland P, Jeka S, Dokoupilová E, Brandt-Jürgens J, Miranda Limón JM, Cantalejo Moreira M, et al. Switching to biosimilar SDZ-ADL in patients with moderate-to-severe active rheumatoid arthritis: 48-week efficacy, safety and immunogenicity results from the phase III, randomized, double-blind ADMYRA study. *BioDrugs* 2020; 34: 809-23.
 21. Blauvelt A, Lacour JP, Fowler JF, Weinberg JM, Gospodinov D, Schuck E, et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. *Br J Dermatol* 2018; 179: 623-31.
 22. Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. *Lancet* 2017; 389: 2304-16.
 23. Moots R, Azevedo V, Coindreau JL, Dörner T, Mahgoub E, Mysler E, et al. Switching between reference biologics and biosimilars for the treatment of rheumatology, gastroenterology, and dermatology inflammatory conditions: considerations for the clinician. *Curr Rheumatol Rep* 2017; 19: 37.
 24. McKinnon RA, Cook M, Liauw W, Marabani M, Marschner IC, Packer NH, et al. Biosimilarity and interchangeability: principles and evidence: a systematic review. *BioDrugs* 2018; 32: 27-52.
 25. Jensen TB, Kim SC, Jimenez-Solem E, Bartels D, Christensen HR, Andersen JT. Shift from adalimumab originator to biosimilars in Denmark. *JAMA Intern Med* 2020; 180: 902-3.
 26. Nabi H, Georgiadis S, Loft AG, Hendricks O, Andersen M, Chrysidis S, et al. Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial. *Ann Rheum Dis* 2021; 80: 1400-9.
 27. Azevedo VF, Babini A, Caballero-Urbe CV, Castañeda-Hernández G, Borlenghi C, Jones HE. Practical guidance on biosimilars, with a focus on Latin America. *J Clin Rheumatol* 2019; 25: 91-100.
 28. Kowalski SC, Benavides JA, Roa PAB, Galarza-Maldonado C, Caballero-Urbe CV, Soriano ER, et al. PANLAR consensus statement on biosimilars. *Clin Rheumatol* 2019; 38: 1485-96.
 29. García Salinas R, Ruta S, Chichande JT, Prado ES, Ruta A, Salvatori F, et al. "Reuma-Check": performance of a comprehensive fast-track program for the diagnosis of axial spondyloarthritis in South America. *J Clin Rheumatol* 2021; 27: 175-81.

Contributions: all authors contributed substantially to the conception and design of the work and acquisition and interpretation of the data. SR and RGS additionally analyzed the data and drafted the initial version of the manuscript. The final manuscript has been revised critically and approved by all the authors, and they have given the necessary attention to ensure the integrity of the work.

Conflict of interest: all authors declare they have no conflicts of interest regarding the present study.

Ethics approval and consent to participate: ethical approval for the study was obtained from the Hospital Italiano de La Plata (evaluation number 25332).

Informed consent: informed consent was obtained from all patients

Patient consent for publication: all patients provided informed consent for the use of their anonymized clinical data for research and publication purposes. No identifiable personal information is included in this manuscript.

Availability of data and materials: data and materials are available from the corresponding author upon request. The findings are fully available.

Funding: none.

Received: 24 May 2024.
Accepted: 26 April 2025.
Early access: 8 May 2025.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

©Copyright: the Author(s), 2025
Licensee PAGEPress, Italy
Reumatismo 2025; 77:1748
doi:10.4081/reumatismo.2025.1748

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.